Announcement on Voluntary Disclosure of Completing Enrollment of the First Subject in Phase III Clinical Trial of BL-M07D1 (HER2 ADC) for Injection for Postoperative Adjuvant Therapy of HER2-Positive Breast Cancer with Residual Invasive Carcinoma after Neoadjuvant Therapy
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
View Attachment
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
View Attachment